These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36879663)

  • 21. High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience.
    Yoon WS; Park JS; Kim YI; Chung DS; Jeun SS; Hong YK; Yang SH
    Asia Pac J Clin Oncol; 2021 Feb; 17(1):123-130. PubMed ID: 32978898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.
    Wendler J; Fox CP; Valk E; Steinheber C; Fricker H; Isbell LK; Neumaier S; Okosun J; Scherer F; Ihorst G; Cwynarski K; Schorb E; Illerhaus G
    BMC Cancer; 2022 Sep; 22(1):971. PubMed ID: 36088292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
    de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J
    Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement of outcomes of an escalated high-dose methotrexate-based regimen for patients with newly diagnosed primary central nervous system lymphoma: a real-world cohort study.
    Li Q; Ma J; Ma Y; Lin Z; Kang H; Chen B
    Cancer Manag Res; 2021; 13():6115-6122. PubMed ID: 34377030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL.
    Takashima Y; Hamano M; Fukai J; Iwadate Y; Kajiwara K; Kobayashi T; Hondoh H; Yamanaka R
    Sci Rep; 2020 May; 10(1):8435. PubMed ID: 32439996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response-adapted treatment with upfront high-dose chemotherapy followed by autologous stem-cell transplantation rescue or consolidation phase high-dose methotrexate for primary central nervous system lymphoma: a long-term mono-center study.
    Nakasu Y; Mitsuya K; Hayashi N; Okamura I; Mori K; Enami T; Tatara R; Nakasu S; Ikeda T
    Springerplus; 2016; 5():307. PubMed ID: 27066340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.
    Isono T; Hira D; Morikochi A; Fukami T; Ueshima S; Nozaki K; Terada T; Morita SY
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00883. PubMed ID: 34664791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
    Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
    Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis.
    Wu Z; Wang C; Lyu Y; Lin Z; Lu M; Wang S; Wang B; Yang N; Li Y; Wang J; Duan X; Zhang N; Gao J; Zhang Y; Hao M; Wang Z; Gao G; Liang R
    Front Oncol; 2023; 13():1104425. PubMed ID: 37056341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma.
    Baraniskin A; Zaslavska E; Nöpel-Dünnebacke S; Ahle G; Seidel S; Schlegel U; Schmiegel W; Hahn S; Schroers R
    Neuro Oncol; 2016 Mar; 18(3):361-7. PubMed ID: 26250566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).
    Miyakita Y; Ohno M; Takahashi M; Muragaki Y; Katai H; Narita Y
    Jpn J Clin Oncol; 2017 Oct; 47(10):919-924. PubMed ID: 28981729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
    Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
    BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
    Yu J; Du H; Ye X; Zhang L; Xiao H
    Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary central nervous system lymphoma: a profile of 26 cases from Western India.
    Agarwal PA; Menon S; Smruti BK; Singhal BS
    Neurol India; 2009; 57(6):756-63. PubMed ID: 20139505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Evaluation of Combination Treatment of Single Agent HD-MTX Chemotherapy up to Three Cycles and Moderate Dose Whole Brain Irradiation for Primary CNS Lymphoma.
    Kobayashi H; Yamaguchi S; Motegi H; Kaneko S; Endou S; Onimaru R; Terasaka S; Houkin K
    J Chemother; 2019 Feb; 31(1):35-41. PubMed ID: 30773132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies.
    Holdhoff M; Wagner-Johnston N; Roschewski M
    Onco Targets Ther; 2020; 13():8323-8335. PubMed ID: 32903865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience.
    Ly KI; Crew LL; Graham CA; Mrugala MM
    Oncol Lett; 2016 May; 11(5):3471-3476. PubMed ID: 27123138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes.
    Gleissner B; Siehl J; Korfel A; Reinhardt R; Thiel E
    Neurology; 2002 Feb; 58(3):390-6. PubMed ID: 11839837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretreatment intratumoral susceptibility signals correlate with response to high-dose methotrexate and progression-free survival in primary central nervous system lymphoma.
    Deguchi S; Nakashima K; Muramatsu K; Mitsuya K; Oishi T; Shirata K; Hayashi N; Sugino T; Endo M; Nakasu Y
    J Clin Neurosci; 2019 Nov; 69():43-50. PubMed ID: 31427235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and Validation of Pretreatment Serum Total Bilirubin as a Biomarker to Predict the Clinical Outcomes in Primary Central Nervous System Lymphoma: A Multicenter Cohort Study.
    Cao J; Li S; Li D; Hua W; Guo L; Xia Z
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.